<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7354743\results\search\disease\results.xml">
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="SARS-CoV-2 in the human population, natural selection tends to select" exact="viral" post="genomes containing fewer CpG motifs that do not trigger"/>
  <result pre="capable of preparing the host immune system for the coronavirus" exact="infection" post="and should be present in SARS-CoV-2 vaccines as strong"/>
  <result pre="delay the fatal meeting of the causative agent of the" exact="disease" post="with those who are pathogen-sensitive or their genetic descendants."/>
  <result pre="will continue to work and COVID-19 will morph into a" exact="disease" post="with mild symptoms in the years to come. However,"/>
  <result pre="so more errors are made when they are copied; also," exact="viral" post="RNA-dependent RNA polymerases do not have a proofreading nuclease"/>
  <result pre="arguably the most powerful medical intervention in the fight against" exact="infectious diseases" post="[2]. Generally, all vaccines work on the same basic"/>
  <result pre="but also cellular, immunity plays a role in protecting against" exact="virus infection" post="[5, 6]. Classic methods involve taking a whole virus,"/>
  <result pre="also cellular, immunity plays a role in protecting against virus" exact="infection" post="[5, 6]. Classic methods involve taking a whole virus,"/>
  <result pre="plays a role in protecting against virus infection [5, 6]." exact="Classic" post="methods involve taking a whole virus, weakening or killing"/>
  <result pre="For the human population, COVID-19 is the third significant coronavirus" exact="infection" post="to occur in the twenty-first century, following severe acute"/>
  <result pre="coronavirus infection to occur in the twenty-first century, following severe" exact="acute" post="respiratory syndrome (SARS) in 2002â€&quot;2003 and Middle East respiratory"/>
  <result pre="infection to occur in the twenty-first century, following severe acute" exact="respiratory" post="syndrome (SARS) in 2002â€&quot;2003 and Middle East respiratory syndrome"/>
  <result pre="to occur in the twenty-first century, following severe acute respiratory" exact="syndrome" post="(SARS) in 2002â€&quot;2003 and Middle East respiratory syndrome (MERS)"/>
  <result pre="severe acute respiratory syndrome (SARS) in 2002â€&quot;2003 and Middle East" exact="respiratory" post="syndrome (MERS) in 2012, which have not stopped yet."/>
  <result pre="acute respiratory syndrome (SARS) in 2002â€&quot;2003 and Middle East respiratory" exact="syndrome" post="(MERS) in 2012, which have not stopped yet. Since"/>
  <result pre="not stopped yet. Since 2012 until 29 February 2020, the" exact="total" post="number of laboratory-confirmed MERS-CoV infection cases reported globally to"/>
  <result pre="until 29 February 2020, the total number of laboratory-confirmed MERS-CoV" exact="infection" post="cases reported globally to WHO is 2538 with 871"/>
  <result pre="Orthomyxoviridae family and are characterized by segmented, negative-strand RNA genomes." exact="Infection" post="with influenza viruses is a constant challenge, burdening peopleâ€™s"/>
  <result pre="challenge, burdening peopleâ€™s health and economies worldwide every year. These" exact="infections" post="cause epidemics that can become pandemics, affecting 5â€&quot;30% of"/>
  <result pre="attenuated influenza vaccines (LAIV). LAIV mimic the course of natural" exact="infections" post="and thus induce a stronger immune response than IIV"/>
  <result pre="some other RNA viruses, this is not so. The human" exact="immunodeficiency" post="virus, types 1 and 2 (HIV-1 and HIV-2), is"/>
  <result pre="RNA viruses, this is not so. The human immunodeficiency virus," exact="types 1 and 2" post="(HIV-1 and HIV-2), is an example of a zoonotic"/>
  <result pre="2 (HIV-1 and HIV-2), is an example of a zoonotic" exact="infection" post="that has spread all over the world without being"/>
  <result pre="the result of multiple cross-species transmissions that occurred when simian" exact="immunodeficiency" post="viruses (SIV) naturally infected African primates [29]. The human"/>
  <result pre="transmissions that occurred when simian immunodeficiency viruses (SIV) naturally infected" exact="African" post="primates [29]. The human immunodeficiency virus (HIV), which consists"/>
  <result pre="immunodeficiency viruses (SIV) naturally infected African primates [29]. The human" exact="immunodeficiency" post="virus (HIV), which consists of two identical negative-sense single-stranded"/>
  <result pre="in clearly defining the specific immune responses responsible for preventing" exact="infection" post="and limiting disease progression. Since early attempts to use"/>
  <result pre="the specific immune responses responsible for preventing infection and limiting" exact="disease" post="progression. Since early attempts to use vaccines to induce"/>
  <result pre="CD8 T lymphocyte response is crucial for immune control of" exact="viral" post="replication has provided an important facet for ongoing efforts"/>
  <result pre="of T cells are known to limit HIV and other" exact="viral" post="infections after the infection has already occurred, their role,"/>
  <result pre="T cells are known to limit HIV and other viral" exact="infections" post="after the infection has already occurred, their role, if"/>
  <result pre="known to limit HIV and other viral infections after the" exact="infection" post="has already occurred, their role, if any, in protecting"/>
  <result pre="already occurred, their role, if any, in protecting against initial" exact="infection" post="is much less clear [2]. HIV-1 is highly mutable."/>
  <result pre="to camouflage the conserved receptor- and coreceptor-binding sites on the" exact="viral" post="envelope (Env) glycoproteins engaged in the virusâ€™s attachment and"/>
  <result pre="a latent provirus that escapes immune recognition owing to the" exact="absence of" post="significant protein expression [32]. Neutralizing antibodies (NAb) typically play"/>
  <result pre="Neutralizing antibodies (NAb) typically play a key role in controlling" exact="viral" post="infections and contribute to the protective effect of many"/>
  <result pre="antibodies (NAb) typically play a key role in controlling viral" exact="infections" post="and contribute to the protective effect of many successful"/>
  <result pre="for humans and the role of NAb in controlling established" exact="infection" post="in humans is also limited. It is clear that"/>
  <result pre="immune selection may be the main reason HIV-1 NAb exert" exact="limited" post="control during infection. Attempts to define NAb capable of"/>
  <result pre="higher in subtypes C and A than in subtype B" exact="infections" post="provides evidence that viral genetic subtype may also be"/>
  <result pre="and A than in subtype B infections provides evidence that" exact="viral" post="genetic subtype may also be important [34, 35]. In"/>
  <result pre="HIV vaccine. Another 'multi-headed beast' sweeping its tracks is the" exact="hepatitis C" post="virus (HCV). HCV is a positive-sense single-stranded RNA virus"/>
  <result pre="news in the form of direct-acting antivirals (DAA) against the" exact="hepatitis C" post="virus (HCV) infection, which have been shown to achieve"/>
  <result pre="virus (HCV) infection, which have been shown to achieve a" exact="complete" post="cure inâ€‰&amp;gt;â€‰95% of cases [47, 48]. It has been"/>
  <result pre="been suggested that DAA have the potential to eliminate an" exact="infection" post="that affects more than 71 million individualsÂ worldwideÂ [49]."/>
  <result pre="important because many individuals do not seek treatment for constant" exact="hepatitis C" post="becauseÂ they are unaware that they are infected. Sadly,"/>
  <result pre="is often a long timeÂ after the initial infection, when" exact="hepatitis C" post="has precipitated serious health issues, that these individuals look"/>
  <result pre="that the development of vaccines that protect against persistent HCV" exact="infection" post="remain a public health priority. Without access to vaccines"/>
  <result pre="public health priority. Without access to vaccines that can limit" exact="viral" post="transmission, even the broad use of highly effective DAA"/>
  <result pre="the virus (NS3-NS5) using chimpanzee adenovirus priming and a modified" exact="vaccinia" post="Ankara (MVA) boost. These represent two of the most"/>
  <result pre="CD4 and CD8 T cells to eliminate infected hepatocytes [55]." exact="Multiple" post="studies of HCV in humans and chimpanzees have provided"/>
  <result pre="have provided strong evidence for the kinetic association between spontaneous" exact="viral" post="clearance and the induction of a broad, sustained group"/>
  <result pre="multiple cytokines and effector functions [57]. For instance, as the" exact="infection" post="is being cleared, virus-specific T cells develop a memory"/>
  <result pre="and potency of the early antibody response can influence the" exact="acute" post="infection outcome and that neutralizing antibodies seem to play"/>
  <result pre="potency of the early antibody response can influence the acute" exact="infection" post="outcome and that neutralizing antibodies seem to play a"/>
  <result pre="antibodies seem to play a part in controlling HCV during" exact="chronic" post="infection [62]. In particular, it is worth noting the"/>
  <result pre="seem to play a part in controlling HCV during chronic" exact="infection" post="[62]. In particular, it is worth noting the data"/>
  <result pre="strategy is to create vaccines based on conservative sequences of" exact="viral" post="genomes using oligonucleotides. Despite the impressive success of currently"/>
  <result pre="impressive success of currently approved adjuvants for generating immunity to" exact="viral" post="and bacterial infections, there remains a need for improved"/>
  <result pre="of currently approved adjuvants for generating immunity to viral and" exact="bacterial infections," post="there remains a need for improved adjuvants that enhance"/>
  <result pre="safe oligonucleotide-based vaccines [66]. For many years, nucleic acids and" exact="short" post="nucleotide molecules have been used as vaccine components. Their"/>
  <result pre="and the cells produced factors that activated macrophages and inhibited" exact="viral" post="growth. The factor that activated the macrophages was interferon"/>
  <result pre="macrophages was interferon (IFN)-gamma and the other factor, which inhibited" exact="viral" post="growth, was IFNalpha/beta. However, the nucleic acid fraction from"/>
  <result pre="et al. reported that unmethylated CpG dinucleotides (CpG ODN) within" exact="bacterial" post="DNA activated host defense mechanisms that led in turn"/>
  <result pre="not sense host-derived â€˜self-moleculesâ€™ but become activated by PAMP during" exact="infection" post="[75]. Ligand binding by TLR3, TLR7, TLR8, and TLR9"/>
  <result pre="first vaccine with a CpG ODN as an adjuvant, for" exact="hepatitis" post="B vaccines [78]. However, it has also been reported"/>
  <result pre="pro-inflammatory cytokines, with the potential risk of developing or worsening" exact="autoimmune diseases" post="and systemic inflammatory response syndrome (SIRS) [79, 80]. TLR9"/>
  <result pre="the potential risk of developing or worsening autoimmune diseases and" exact="systemic" post="inflammatory response syndrome (SIRS) [79, 80]. TLR9 agonists have"/>
  <result pre="of developing or worsening autoimmune diseases and systemic inflammatory response" exact="syndrome" post="(SIRS) [79, 80]. TLR9 agonists have demonstrated a substantial"/>
  <result pre="and as mono- or combination therapies for the treatment of" exact="cancer" post="and infectious and allergic diseases. Commonly referred to as"/>
  <result pre="mono- or combination therapies for the treatment of cancer and" exact="infectious" post="and allergic diseases. Commonly referred to as CpG oligodeoxynucleotides"/>
  <result pre="indicate that CpG ODN improve the activity of vaccines targeting" exact="infectious diseases" post="and cancer. Clinical trials demonstrate that CpG ODN have"/>
  <result pre="neutralizing antibody titers and the memory B cell response are" exact="short" post="lived in SARS-recovered patients and the antibody will only"/>
  <result pre="in SARS-recovered patients and the antibody will only target the" exact="primary" post="homologous strain. Follow-up studies from patients who recovered from"/>
  <result pre="memory T cells provide better protection, boosting both local and" exact="systemic" post="memory T cell responses would be a more useful"/>
  <result pre="humans and animals become highly susceptible to SARS-CoV and other" exact="respiratory" post="virus infections. Such an age-dependent increase in susceptibility is"/>
  <result pre="[85]. Virus-specific CD8 T cells play a critical role in" exact="viral" post="clearance; CD4 T cells provide the necessary support for"/>
  <result pre="cells [86]. Generally, results suggest that the role of virus-specific" exact="primary" post="CD4 and CD8 T cell responses to respiratory or"/>
  <result pre="of virus-specific primary CD4 and CD8 T cell responses to" exact="respiratory" post="or other coronavirus infections are both virus and mouse"/>
  <result pre="and CD8 T cell responses to respiratory or other coronavirus" exact="infections" post="are both virus and mouse strain dependent [81]; in"/>
  <result pre="the genetic component of the host-virus relationship. Eventually, in the" exact="absence of" post="vaccines and drugs, natural selection will rapidly lead to"/>
  <result pre="apparent selection against CpG dinucleotides operating on both host and" exact="viral" post="cytoplasmic RNA sequences remains unexplained. Table 1 Occurrence of"/>
  <result pre="observed that elevated frequencies of both UpA and CpG attenuated" exact="viral" post="replication, whereas frequencies lower than those of native viral"/>
  <result pre="of both UpA and CpG attenuated viral replication, whereas frequencies" exact="lower" post="than those of native viral sequences enhanced replication [99]."/>
  <result pre="attenuated viral replication, whereas frequencies lower than those of native" exact="viral" post="sequences enhanced replication [99]. However, our thinking goes in"/>
  <result pre="SARS-CoV-2 in the human population, natural selection tends to favor" exact="viral" post="genomes containing fewer CpG motifs so as not to"/>
  <result pre="'neck' and may have a positive inhibitory effect during possible" exact="acute" post="inflammation that occurs after vaccination. As the body temperature"/>
  <result pre="believed that SARS-CoV-2 dampens antiviral interferon responses, which results in" exact="uncontrolled" post="viral replication. For the other coronaviruses, SARS-CoV and MERS-CoV,"/>
  <result pre="that SARS-CoV-2 dampens antiviral interferon responses, which results in uncontrolled" exact="viral" post="replication. For the other coronaviruses, SARS-CoV and MERS-CoV, the"/>
  <result pre="For the other coronaviruses, SARS-CoV and MERS-CoV, the response to" exact="viral infection" post="by type I IFN is suppressed. The influx of"/>
  <result pre="the other coronaviruses, SARS-CoV and MERS-CoV, the response to viral" exact="infection" post="by type I IFN is suppressed. The influx of"/>
  <result pre="coronaviruses, SARS-CoV and MERS-CoV, the response to viral infection by" exact="type I" post="IFN is suppressed. The influx of neutrophils and monocytes/macrophages"/>
  <result pre="hard to stop. For instance, the cytokine storm can initiate" exact="viral" post="sepsis and inflammatory-induced lung injury, which leads to other"/>
  <result pre="mortality rate seen among young adults during the outbreak [120]." exact="Severe" post="influenza infections caused by highly virulent subtypes such H1N1"/>
  <result pre="seen among young adults during the outbreak [120]. Severe influenza" exact="infections" post="caused by highly virulent subtypes such H1N1 and H5N1"/>
  <result pre="induction of the pro-inflammatory cytokines TNF-Î±, IL-1Î², IL-6, IL-8, and" exact="monocyte" post="chemoattractant protein-1 (MCP-1) [121, 122], which eventually results in"/>
  <result pre="eventually results in multiple organ dysfunction and failure and increased" exact="vascular" post="hyperpermeability [122]. With respect to the tendency of the"/>
  <result pre="overexpress cytokines and let loose a â€˜cytokine stormâ€™ during coronavirus" exact="infection" post="in some humans, we are proposing vaccine construct having"/>
  <result pre="peopleâ€™s immune systems train for this inflammation reaction in the" exact="absence of" post="a real pathogen and real danger. In a broad"/>
  <result pre="vaccines against a large number of pathogens, including influenza virus," exact="measles" post="virus, lymphocytic choriomeningitis virus, orthopoxviruses, and other viruses [71]."/>
  <result pre="a large number of pathogens, including influenza virus, measles virus," exact="lymphocytic choriomeningitis" post="virus, orthopoxviruses, and other viruses [71]. At the height"/>
  <result pre="FZEG-2020-0060 of the Ministry of Science and Higher Education of" exact="Russian" post="Federation. References References 1.AndersenKGRambautALipkinWIet al.The proximal origin of SARS-CoV-2Nat"/>
  <result pre="aspects of humoral and cellular immunity in naturally occuring feline" exact="infectious" post="peritonitisVet Immunol Immunopathol1998652052209839875 6.LoaCCLinTLWuCCBryanTThackerHLHooperTSchraderDHumoral and cellular immune responses in"/>
  <result pre="poults infected with turkey coronavirusPoult Sci2001801416142411599699 7.HeYJiangSVaccine design for severe" exact="acute" post="respiratory syndrome coronavirusViral Immunol20051832733216035944 8.LinJTZhangJSSuNXuJGWangNChenJTChenXLiuYXGaoHJiaYPSafety and immunogenicity from a"/>
  <result pre="infected with turkey coronavirusPoult Sci2001801416142411599699 7.HeYJiangSVaccine design for severe acute" exact="respiratory" post="syndrome coronavirusViral Immunol20051832733216035944 8.LinJTZhangJSSuNXuJGWangNChenJTChenXLiuYXGaoHJiaYPSafety and immunogenicity from a phase"/>
  <result pre="with turkey coronavirusPoult Sci2001801416142411599699 7.HeYJiangSVaccine design for severe acute respiratory" exact="syndrome" post="coronavirusViral Immunol20051832733216035944 8.LinJTZhangJSSuNXuJGWangNChenJTChenXLiuYXGaoHJiaYPSafety and immunogenicity from a phase I"/>
  <result pre="and immunogenicity from a phase I trial of inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccineAntivir Ther (Lond)2007121107111318018769 9.MartinJELouderMKHolmanLAGordonIJEnamaMELarkinBDAndrewsCAVogelLKoupRARoedererMVRC 301 Study"/>
  <result pre="immunogenicity from a phase I trial of inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccineAntivir Ther (Lond)2007121107111318018769 9.MartinJELouderMKHolmanLAGordonIJEnamaMELarkinBDAndrewsCAVogelLKoupRARoedererMVRC 301 Study Team"/>
  <result pre="from a phase I trial of inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccineAntivir Ther (Lond)2007121107111318018769 9.MartinJELouderMKHolmanLAGordonIJEnamaMELarkinBDAndrewsCAVogelLKoupRARoedererMVRC 301 Study Team A"/>
  <result pre="influenza vaccinesClin Microbiol Rev20132647649223824369 16.RanZShenHLangYKolbEATuranNZhuLet al.Domestic pigs are susceptible to" exact="infection" post="with influenza B virusesJ Virol20158994818482625673727 17.HeoJYSongJYNohJYChoiMJYoonJGLeeSNCheongHJKimWJEffects of influenza immunization"/>
  <result pre="with influenza B virusesJ Virol20158994818482625673727 17.HeoJYSongJYNohJYChoiMJYoonJGLeeSNCheongHJKimWJEffects of influenza immunization on" exact="pneumonia" post="in the elderlyHum Vacc Immuno20171744749 18.SiriwardenaANIncreasing evidence that influenza"/>
  <result pre="Vacc Immuno20171744749 18.SiriwardenaANIncreasing evidence that influenza is a trigger for" exact="cardiovascular" post="diseaseJ Infect Dis20122061636163823048169 19.SridharSBrokstadKACoxRJInfluenza Vaccination Strategies: Comparing Inactivated and"/>
  <result pre="for a One Health approachOne Health.202010124 27.ParrishCRMurciaPRHolmesECInfluenza virus reservoirs and" exact="intermediate" post="hosts: dogs, horses, and new possibilities for influenza virus"/>
  <result pre="new possibilities for influenza virus exposure of humansJ Virol20158962990299425540375 28.LuciwPAFieldsBNHuman" exact="immunodeficiency" post="viruses and their replicationVirology19963PhiladelphiaLippincott-Raven18811952 29.SharpPMHahnBHOrigins of HIV and the"/>
  <result pre="activity in a geographically diverse East London cohort of human" exact="immunodeficiency" post="virus type 1-infected patients: Clade C infection results in"/>
  <result pre="cohort of human immunodeficiency virus type 1-infected patients: Clade C" exact="infection" post="results in a stronger and broader humoral immune response"/>
  <result pre="SilvaJAllenTMHortonHVenhamJERudersdorfJAVogelTPauzaCDBontropREDeMarsRSetteAHughesALWatkinsDIVirus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian" exact="immunodeficiency" post="virusEnv Nef Nat Med199951270127610545993 39.ParrenPWMooreJPBurtonDRSattentauQJThe neutralizing antibody response to"/>
  <result pre="virusEnv Nef Nat Med199951270127610545993 39.ParrenPWMooreJPBurtonDRSattentauQJThe neutralizing antibody response to HIV-1:" exact="viral" post="evasion and escape from humoral immunityAIDS19991313716210207558 40.KorberBGaschenBYusimKThakallapallyRKesmirCDetoursVEvolutionary and immunological"/>
  <result pre="diversity of HIV-1AIDS2000143314410714565 42.FornsXBukhJPurcellRHThe challenge of developing a vaccine against" exact="hepatitis C" post="virusJ Hepatol20023768469512399239 43.PybusOGThezeJHepacivirus cross-species transmission and the origins of"/>
  <result pre="virusJ Hepatol20023768469512399239 43.PybusOGThezeJHepacivirus cross-species transmission and the origins of the" exact="hepatitis C" post="virusCurr Opin Virol20061617 44.DrexlerJFCormanVMMÃ¼llerMALukashevANGmylACoutardBAdamARitzDLeijtenLMvan RielDKalliesRKloseSMGloza-RauschFBingerTAnnanAAdu-SarkodieYOppongSBourgarelMRuppDHoffmannBSchlegelMKÃ¼mmererBMKrÃ¼gerDHSchmidt-ChanasitJSetiÃ©nAACottontailVMHemachudhaTWacharapluesadeeSOsterriederKBartenschlagerRMattheeSBeerMKuikenTReuskenCLeroyEMUlrichRGDrostenCEvidence for novel hepaciviruses in"/>
  <result pre="a wild Old World primateJ of Virol2013878971898123740998 47.PawlotskyJMFeldJJZeuzemSHoofnagleJHFrom non-A, non-B" exact="hepatitis" post="to hepatitis C virus cureJ Hepatol2015628799 48.Falade-NwuliaOSuarez-CuervoCNelsonDRFriedMWSegalJBSulkowskiMSOral direct-acting agent"/>
  <result pre="Old World primateJ of Virol2013878971898123740998 47.PawlotskyJMFeldJJZeuzemSHoofnagleJHFrom non-A, non-B hepatitis to" exact="hepatitis C" post="virus cureJ Hepatol2015628799 48.Falade-NwuliaOSuarez-CuervoCNelsonDRFriedMWSegalJBSulkowskiMSOral direct-acting agent therapy for hepatitis"/>
  <result pre="hepatitis C virus cureJ Hepatol2015628799 48.Falade-NwuliaOSuarez-CuervoCNelsonDRFriedMWSegalJBSulkowskiMSOral direct-acting agent therapy for" exact="hepatitis C" post="virus infection: a systematic reviewAnn Intern Med2017166963764828319996 49.collab: WHOGlobal"/>
  <result pre="C virus infection: a systematic reviewAnn Intern Med2017166963764828319996 49.collab: WHOGlobal" exact="Hepatitis" post="Report Geneva2017SwitzerlandWHO 50.GravitzLIntroduction: a smouldering public-health crisisNature201147424 51.CoxALMEDICINE. Global"/>
  <result pre="Geneva2017SwitzerlandWHO 50.GravitzLIntroduction: a smouldering public-health crisisNature201147424 51.CoxALMEDICINE. Global control of" exact="hepatitis C" post="virusScience201534979079126293940 52.Falade-NwuliaOSulkowskiMSMerkowALatkinCMehtaSHUnderstanding and addressing hepatitis C reinfection in the"/>
  <result pre="51.CoxALMEDICINE. Global control of hepatitis C virusScience201534979079126293940 52.Falade-NwuliaOSulkowskiMSMerkowALatkinCMehtaSHUnderstanding and addressing" exact="hepatitis C" post="reinfection in the oral direct-acting antiviral eraJ Viral Hepat20182522022729316030"/>
  <result pre="addressing hepatitis C reinfection in the oral direct-acting antiviral eraJ" exact="Viral" post="Hepat20182522022729316030 53.FreySEHoughtonMCoatesSAbrignaniSChienDRosaDet al.Safety and immunogenicity of HCV E1E2 vaccine"/>
  <result pre="vaccine adjuvanted with MF59 administered to healthy adultsVaccine2010286367637320619382 54.LawJLChenCWongJHockmanDSanterDMFreySEet al.A" exact="hepatitis C" post="virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from"/>
  <result pre="ONE20138e5977623527266 55.ShoukryNHHepatitisCVaccines, antibodies, and T CellsFront Immunol20189929403493 56.Abdel-HakeemMSShoukryNHProtective immunity against" exact="hepatitis" post="C: many shades of grayFront Immunol2014527424982656 57.BadrGBedardNAbdel-HakeemMSTrautmannLWillemsBVilleneuveJPet al.Early interferon"/>
  <result pre="many shades of grayFront Immunol2014527424982656 57.BadrGBedardNAbdel-HakeemMSTrautmannLWillemsBVilleneuveJPet al.Early interferon therapy for" exact="hepatitis C" post="virus infection rescues polyfunctional, long-lived CD8+ memory T cellsJ"/>
  <result pre="of grayFront Immunol2014527424982656 57.BadrGBedardNAbdel-HakeemMSTrautmannLWillemsBVilleneuveJPet al.Early interferon therapy for hepatitis C" exact="virus infection" post="rescues polyfunctional, long-lived CD8+ memory T cellsJ Virol2008825 58.Golden-MasonLBurtonJRJrCastelblancoNKlarquistJBenllochSWangCet"/>
  <result pre="grayFront Immunol2014527424982656 57.BadrGBedardNAbdel-HakeemMSTrautmannLWillemsBVilleneuveJPet al.Early interferon therapy for hepatitis C virus" exact="infection" post="rescues polyfunctional, long-lived CD8+ memory T cellsJ Virol2008825 58.Golden-MasonLBurtonJRJrCastelblancoNKlarquistJBenllochSWangCet"/>
  <result pre="Virol2008825 58.Golden-MasonLBurtonJRJrCastelblancoNKlarquistJBenllochSWangCet al.Loss of IL-7 receptor alpha-chain (CD127) expression in" exact="acute" post="HCV infection associated with viral persistenceHepatology2006441098110910.1002/hep.2136517058243 59.BengschBSpangenbergHCKerstingNNeumann-HaefelinCPantherEVon WeizsackerFet al.Analysis"/>
  <result pre="al.Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV" exact="infection" post="associated with viral persistenceHepatology2006441098110910.1002/hep.2136517058243 59.BengschBSpangenbergHCKerstingNNeumann-HaefelinCPantherEVon WeizsackerFet al.Analysis of CD127"/>
  <result pre="receptor alpha-chain (CD127) expression in acute HCV infection associated with" exact="viral" post="persistenceHepatology2006441098110910.1002/hep.2136517058243 59.BengschBSpangenbergHCKerstingNNeumann-HaefelinCPantherEVon WeizsackerFet al.Analysis of CD127 and KLRG1 expression"/>
  <result pre="persistenceHepatology2006441098110910.1002/hep.2136517058243 59.BengschBSpangenbergHCKerstingNNeumann-HaefelinCPantherEVon WeizsackerFet al.Analysis of CD127 and KLRG1 expression on" exact="hepatitis C" post="virus-specific CD8+ T cells reveals the existence of different"/>
  <result pre="reveals the existence of different memory T-cell subsets in the" exact="peripheral" post="blood and liverJ Virol20078194595317079288 60.ShinECParkSHNascimbeniMMajorMCaggiariLDe ReVet al.The frequency of"/>
  <result pre="not the expression of exhaustion markers predict the outcome of" exact="acute" post="hepatitis C virus infectionJ Virol20138784772477723388706 61.GuptaPKGodecJWolskiDAdlandEYatesKPaukenKEet al.CD39 expression identifies"/>
  <result pre="the expression of exhaustion markers predict the outcome of acute" exact="hepatitis C" post="virus infectionJ Virol20138784772477723388706 61.GuptaPKGodecJWolskiDAdlandEYatesKPaukenKEet al.CD39 expression identifies terminally exhausted"/>
  <result pre="Pathog201511e100517726485519 62.BallJKTarrAWMcKeatingJAThe past, present and future of neutralizing antibodies for" exact="hepatitis C" post="virusAntiviral Res201410510010011124583033 63.LawMMaruyamaTLewisJGiangETarrAWStamatakiZet al.Broadly neutralizing antibodies protect against hepatitis"/>
  <result pre="hepatitis C virusAntiviral Res201410510010011124583033 63.LawMMaruyamaTLewisJGiangETarrAWStamatakiZet al.Broadly neutralizing antibodies protect against" exact="hepatitis C" post="virus quasispecies challengeNat Med200814252718064037 64.GiangEDornerMPrentoeJCDreuxMEvansMJBukhJet al.Human broadly neutralizing antibodies"/>
  <result pre="al.Human broadly neutralizing antibodies to the envelope glycoprotein complex of" exact="hepatitis C" post="virusProc Natl Acad Sci USA20121096205621022492964 65.BaileyJRFlyakAICohenVJLiHWasilewskiLNSniderAEet al.Broadly neutralizing antibodies"/>
  <result pre="USA20121096205621022492964 65.BaileyJRFlyakAICohenVJLiHWasilewskiLNSniderAEet al.Broadly neutralizing antibodies with few somatic mutations and" exact="hepatitis C" post="virus clearanceJCI Insight201729e92872 66.Batista-DuharteASendraLHerreroMJTÃ©llez-MartÃ­nezDCarlosIZAliÃ±oSFProgress in the Use of Antisense"/>
  <result pre="72.ScheiermannJKlinmanDMClinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting" exact="infectious diseases" post="and cancerVaccine2014326377638924975812 73.YamamotoSYamamotoTShimadaSKuramotoEYanoOKataokaTTokunagaTDNA from bacteria, but not from vertebrates,"/>
  <result pre="from vertebrates, induces interferons, activates natural killer cells and inhibits" exact="tumor" post="growthMicrobiol Immunol1992369839971281260 74.KriegAMYiAKMatsonSWaldschmidtTJBishopGATeasdaleRKoretzkyGAKlinmanDMCpG motifs in bacterial DNA trigger direct"/>
  <result pre="killer cells and inhibits tumor growthMicrobiol Immunol1992369839971281260 74.KriegAMYiAKMatsonSWaldschmidtTJBishopGATeasdaleRKoretzkyGAKlinmanDMCpG motifs in" exact="bacterial" post="DNA trigger direct B-cell activationNature19953745465497700380 75.JanewayCAMedzhitovRInnate immune recognitionAnnu Rev"/>
  <result pre="autoaggression against hepatocytesEur J Immunol2002323628363712516551 81.ChannappanavarRZhaoJPerlmanST cell-mediated immune response to" exact="respiratory" post="coronavirusesImmunol Res2014591â€&quot;311812824845462 82.PeirisJSGuanYYuenKYSevere acute respiratory syndromeNat Med200410S88S9715577937 83.MuraskoDMJiangJResponse of"/>
  <result pre="Immunol2002323628363712516551 81.ChannappanavarRZhaoJPerlmanST cell-mediated immune response to respiratory coronavirusesImmunol Res2014591â€&quot;311812824845462 82.PeirisJSGuanYYuenKYSevere" exact="acute" post="respiratory syndromeNat Med200410S88S9715577937 83.MuraskoDMJiangJResponse of aged mice to primary"/>
  <result pre="81.ChannappanavarRZhaoJPerlmanST cell-mediated immune response to respiratory coronavirusesImmunol Res2014591â€&quot;311812824845462 82.PeirisJSGuanYYuenKYSevere acute" exact="respiratory" post="syndromeNat Med200410S88S9715577937 83.MuraskoDMJiangJResponse of aged mice to primary virus"/>
  <result pre="82.PeirisJSGuanYYuenKYSevere acute respiratory syndromeNat Med200410S88S9715577937 83.MuraskoDMJiangJResponse of aged mice to" exact="primary" post="virus infectionsImmunol Rev200520528529615882361 84.GardnerEMGonzalezEWNogusaSMuraskoDMAge-related changes in the immune response"/>
  <result pre="a racially diverse, healthy elderly populationVaccine2006241609161416260072 85.RobertsADemingDPaddockCDChengAYountBVogelLHermanBDSheahanTHeiseMGenrichGLZakiSRBaricRSubbaraoKA mouse-adapted SARS-coronavirus causes" exact="disease" post="and mortality in BALB/c micePLoS Pathog20073e517222058 86.WilliamsonJSStohlmanSAEffective clearance of"/>
  <result pre="and mortality in BALB/c micePLoS Pathog20073e517222058 86.WilliamsonJSStohlmanSAEffective clearance of mouse" exact="hepatitis" post="virus from the central nervous system requires both CD4+"/>
  <result pre="micePLoS Pathog20073e517222058 86.WilliamsonJSStohlmanSAEffective clearance of mouse hepatitis virus from the" exact="central nervous system" post="requires both CD4+ and CD8+ T cellsJ Virol199064458945922166833 87.RothYChapnikJSColePFeasibility"/>
  <result pre="Hyg201510917518125636950 89.HodgsonJThe pandemic pipelineNat Biotechnol202048 90.GottliebJZamoraMRHodgesTMuskAWSommerwerkUDillingDArcasoySDeVincenzoJKarstenVShahSet al.ALN-RSV01 for prevention of" exact="bronchiolitis" post="obliterans syndrome after respiratory syncytial virus infection in lung"/>
  <result pre="pandemic pipelineNat Biotechnol202048 90.GottliebJZamoraMRHodgesTMuskAWSommerwerkUDillingDArcasoySDeVincenzoJKarstenVShahSet al.ALN-RSV01 for prevention of bronchiolitis obliterans" exact="syndrome" post="after respiratory syncytial virus infection in lung transplant recipientsJ"/>
  <result pre="Biotechnol202048 90.GottliebJZamoraMRHodgesTMuskAWSommerwerkUDillingDArcasoySDeVincenzoJKarstenVShahSet al.ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after" exact="respiratory" post="syncytial virus infection in lung transplant recipientsJ Heart Lung"/>
  <result pre="al.ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial" exact="virus infection" post="in lung transplant recipientsJ Heart Lung Transplant20163521322126452996 91.LatzESchoenemeyerAVisintinAFitzgeraldKAMonksBGKnetterCFLienENilsenNJEspevikTGolenbockDTTLR9 signals"/>
  <result pre="for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus" exact="infection" post="in lung transplant recipientsJ Heart Lung Transplant20163521322126452996 91.LatzESchoenemeyerAVisintinAFitzgeraldKAMonksBGKnetterCFLienENilsenNJEspevikTGolenbockDTTLR9 signals"/>
  <result pre="syndrome after respiratory syncytial virus infection in lung transplant recipientsJ" exact="Heart" post="Lung Transplant20163521322126452996 91.LatzESchoenemeyerAVisintinAFitzgeraldKAMonksBGKnetterCFLienENilsenNJEspevikTGolenbockDTTLR9 signals after translocating from the ER"/>
  <result pre="with TLR9 bindingInt Immunol20112320321421393636 96.Glasspool-MaloneJSteenlandPRMcDonaldRJSanchezRAWattsTLZabnerJMaloneRWDNA transfection of macaque and murine" exact="respiratory" post="tissue is greatly enhanced by use of a nuclease"/>
  <result pre="nuclease inhibitorJ Gene Med2002432333212112649 97.DiasNSteinCAAntisense oligonucleotides: basic concepts and mechanismsMol" exact="Cancer" post="Ther2002134735512489851 98.HaasTet al.The DNA sugar backbone 2â€² deoxyribose determines"/>
  <result pre="and enhanced replicationNucleic Acids Res2014424527454524470146 100.GreenbaumBDRabadanRLevineAJPatterns of oligonucleotide sequences in" exact="viral" post="and host cell RNA identify mediators of the host"/>
  <result pre="a commotion in the blood: immunotherapy progresses from bacteria to" exact="bacterial" post="DNAImmunol Today20002152152611071532 105.BallasZKRasmussenWLKriegAMInduction of NK activity in murine and"/>
  <result pre="murine and human cells by CpG motifs in oligodeoxynucleotides and" exact="bacterial" post="DNAJ Immunol19961575184018458757300 106.YamamotoSYamamotoTKataokaTKuramotoEYanoOTokunagaTUnique palindromic sequences in synthetic oligonucleotides are"/>
  <result pre="function of a newly identified CpG DNA motif in human" exact="primary" post="B cellsJ Immunol2000164294495310623843 109.HartmannGWeeratnaRDBallasZKPayettePBlackwellSSupartoIRasmussenWLWaldschmidtMSajuthiDPurcellHDavisHLKriegAMDelineation of a CpG phosphorothioate oligodeoxynucleotide"/>
  <result pre="lentiviral genes: a possible role of methylation in regulation of" exact="viral" post="expressionNucleic Acids Res19901819579357972170945 115.KriegAMLymphocyte activation by CpG dinucleotide motifs"/>
  <result pre="novel coronavirus in WuhanChina Lancet202039549750631986264 120.PerroneLAPlowdenJKGarcia-SastreAKatzJMTumpeyTMH5N1 and 1918 pandemic influenza" exact="virus infection" post="results in early and excessive infiltration of macrophages and"/>
  <result pre="coronavirus in WuhanChina Lancet202039549750631986264 120.PerroneLAPlowdenJKGarcia-SastreAKatzJMTumpeyTMH5N1 and 1918 pandemic influenza virus" exact="infection" post="results in early and excessive infiltration of macrophages and"/>
  <result pre="of micePLoS Pathog20084e100011518670648 121.WangSYLeTQKuriharaNChidaJCisseYYanoMKidoHInfluenza virus-cytokine-protease cycle in the pathogenesis of" exact="vascular" post="hyperpermeability in severe influenzaJ Infect Dis2010202991100120731583 122.ChengXWLuJAWuCLYiLNXieXShiXDFangSSZanHKungHFHeMLThree fatal cases"/>
  <result pre="Infect Dis2010202991100120731583 122.ChengXWLuJAWuCLYiLNXieXShiXDFangSSZanHKungHFHeMLThree fatal cases of pandemic 2009 influenza A" exact="virus infection" post="in Shenzhen are associated with cytokine stormRespir Physiol Neurobiol201117518518721075220"/>
  <result pre="Dis2010202991100120731583 122.ChengXWLuJAWuCLYiLNXieXShiXDFangSSZanHKungHFHeMLThree fatal cases of pandemic 2009 influenza A virus" exact="infection" post="in Shenzhen are associated with cytokine stormRespir Physiol Neurobiol201117518518721075220"/>
 </snippets>
</snippetsTree>
